Clear Cell Renal Cell Carcinoma Clinical Trial
Official title:
89Zr-DFO-GmAb PET/CT vs Contrast-Enhanced CT for Detection of Recurrent Clear Cell Renal Cell Carcinoma After Surgery
Verified date | March 2024 |
Source | Jonsson Comprehensive Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II trial compares the safety and effectiveness of 89Zr-DFO-GmAb positron emission tomography (PET)/computed tomography (CT) compared to contrast-enhanced CT after surgery in detecting clear cell renal cell cancer that has come back (recurrent). For some patients, the risk of recurrence after surgery remains high. Conventional CT methods, such as contrast-enhanced CT, may not detect small volume or micrometastatic disease. PET/CT with radiotracers, such as 89Zr-DFO-GmAb, may improve detection of tumor cells. Girentuximab (GmAb), a monoclonal antibody, is tagged with zirconium-89, a radioactive atom (which is also known as an isotope). The zirconium-89 (89Zr) isotope is attached to girentuximab with desferrioxamine (DFO) and this combined product is called 89Zr-DFO-girentuximab. 89Zr-DFO-girentuximab attaches itself to a protein on the surface of clear cell renal cell tumor cells called CAIX. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 89Zr-DFO-GmAb. Because some cancers, including clear cell renal cell cancer, take up 89Zr-DFO-GmAb it can be seen with PET. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient's body. Using contrast agents with CT scan to enhance the images (contrast-enhanced CT) is standard of care imaging. 89Zr-DFO-GmAb PET/CT may be safe and effective compared to contrast-enhanced CT in detecting recurrent clear cell renal cell cancer after surgery.
Status | Not yet recruiting |
Enrollment | 91 |
Est. completion date | June 1, 2030 |
Est. primary completion date | June 1, 2029 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age = 18 - Histologically confirmed clear cell renal cell carcinoma (RCC) (ccRCC) (based on partial/radical nephrectomy/metastasectomy) - For tumors with extensive sarcomatoid features, if there is evidence of areas of clear cell and high CAIX expression throughout the tumor on immunohistochemistry, they will be allowed on study - Subjects must have undergone definitive treatment of their primary tumor (partial/radical nephrectomy) +/- resection of metastatic disease to no evidence of disease (NED) with a prior nephrectomy < 2 years) - Surgery must have been performed between 4-16 weeks at the time of planned imaging - Subjects are considered to have a high risk of recurrence based on the following criteria: - Intermediate-high risk ccRCC: - pathologic tumor stage 2 (pT2), grade 4, or sarcomatoid, N0, M0 - pathologic tumor stage 3 (pT3), any grade, N0, M0 - High risk ccRCC: - pathologic tumor stage 4 (pT4), any grade, N0, M0 - pT any stage, any grade, number of positive nodes (pN+), M0 - M1 now NED: pathologically-confirmed ccRCC, undergoing a resection of a solitary, isolated soft tissue metastasis within two years from initial nephrectomy - Negative serum pregnancy tests in female patients of childbearing potential. (Women of child bearing potential [WOCBP] require a negative pregnancy test within 24 hours (urine) prior to receiving investigational product) - Consent to practice double-barrier contraception until a minimum of 42 days after 89Zr-DFO-GmAb administration - Individual must be able to remain still and lie flat for duration of the diagnostic imaging procedure (less than 1 hour) Exclusion Criteria: - Inability to provide written informed consent - Any evidence of residual disease or known metastasis at the time of planned 89Zr-DFO-GmAb administration - Prior post-operative imaging for confirmation of disease status - An untreated non-renal malignancy with the following exceptions: - Low risk prostate cancer on active surveillance (National Comprehensive Cancer Network [NCCN] very low/low risk) - Non-melanoma skin cancer - Any prior treated malignancy meeting the following characteristics: - Treated stage I or II cancer from which the patient is currently in complete remission - A stage III cancer from which the patient is progressing or has been disease-free for and has required active treatment (e.g. adjuvant or maintenance therapy) within the past 3 years prior to enrollment - A hematologic malignancy from which the patient is currently in complete remission - Contraindication to the use of iodinated contrast-enhanced CT agents, based on: - Severe allergy (for which pre-medication cannot limit adverse reactions) or - Estimated glomerular filtration rate (GFR) = 30 ml/min/1.73m^2 - Prior use of systemic therapy treatment for kidney cancer (PD-1, PD-L1, tyrosine kinase or TOR inhibitor) or radiotherapy within 4 weeks of enrollment - Exposure to experimental diagnostic or therapeutic drug within 14 days from date of planned administration - Women who are pregnant or breastfeeding - Known hypersensitivity to girentuximab - Known inability to remain still and lie flat imaging procedure (about 30 minutes) |
Country | Name | City | State |
---|---|---|---|
United States | UCLA / Jonsson Comprehensive Cancer Center | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
Jonsson Comprehensive Cancer Center | Telix Pharmaceuticals (Innovations) Pty Limited |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Lesion detection rate | Patients will be treated as binary categorization as follows: (i) Patients who have = 1 lesion confirmed to be recurrent disease will be designated positive (recurrence). (ii) Patients with no lesions detected will be designated negative (no recurrence). The analysis of the primary objective will utilize McNemar's test to compare the detection rate between the imaging techniques. | Up to 16 weeks from surgical resection | |
Secondary | Incidence of adverse events (AEs) | The total number of AEs will be summarized with grade and attribution. The total number of significant AEs will be summarized with attribution if present. AEs will be descriptive in nature and only counts and percentage will be reported. | Up to day 14 | |
Secondary | Positive predictive value (PPV) | Will compare PPV of 89Zr-DFO-GmAb PET/CT in subjects designated as having a suspicious lesion on the BICR PET/CT evaluation, will review follow up for available lesion validation by 1) histopathology (biopsy/resection), 2) evidence of growth under surveillance or 3) reduction of size under treatment, and 4) unequivocal confirmation of malignancy on a different imaging modality. As there are no firm estimates to the number of lesions that will be designated as suspicious, there are no planned statistical analyses planned. Would present the total number of cases and the frequency of validation with the 95% confidence interval. | Up to 2 years | |
Secondary | Recurrence-free survival | Recurrence-free survival will be calculated using the Kaplan-Meier Method with date and evidence of recurrence based on either clinical annotation by the treating physician or documentation of recurrence by diagnostic imaging or histopathology. Analysis will be descriptive and provide an estimated 2-year recurrence-free survival with 95% confidence interval. A Log-rank test will compare the differences in recurrence-free survival between groups. | Up to 2 years | |
Secondary | Change in management and perceived clinical utility of the unblinded read/report of positron emission tomography/ computed tomography (PET/CT) | Questionnaires using Likert scores will be used to determine changes. Analysis will be descriptive. | At baseline and up to 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03163667 -
CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)
|
Phase 2 | |
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
Withdrawn |
NCT02307474 -
A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer
|
N/A | |
Completed |
NCT00101114 -
Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer
|
Phase 2 | |
Completed |
NCT00078858 -
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
|
Phase 1/Phase 2 | |
Recruiting |
NCT05363631 -
Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab
|
Phase 1/Phase 2 | |
Terminated |
NCT01198158 -
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy
|
Phase 3 | |
Completed |
NCT00378703 -
Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
|
Phase 2 | |
Recruiting |
NCT06138496 -
Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
|
Phase 2 | |
Recruiting |
NCT06088134 -
Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)
|
||
Recruiting |
NCT06049576 -
Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
|
Phase 1 | |
Active, not recruiting |
NCT01038778 -
Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05536141 -
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05119335 -
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
Completed |
NCT01243359 -
Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies
|
Phase 1 | |
Terminated |
NCT00098618 -
Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
|
Phase 2 | |
Recruiting |
NCT05620134 -
Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT06052852 -
Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT03680521 -
Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT06195150 -
Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal Cancer
|